WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Abrir esta carpeta y ver su contenidoInsect and arachnid bites and stings
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Abrir esta carpeta y ver su contenidoViral infections
Abrir esta carpeta y ver su contenidoEczematous diseases
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Cerrar esta carpetaPremalignant lesions and malignant tumours
Ver el documentoActinic keratosis
Ver el documentoBasal cell and squamous cell carcinomas
Ver el documentoMalignant melanoma
Abrir esta carpeta y ver su contenidoPhotodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Abrir esta carpeta y ver su contenidoAnti-inflammatory and antipruritic drugs1
Abrir esta carpeta y ver su contenidoAntiallergics and drugs used in anaphylaxis
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Premalignant lesions and malignant tumours

Exposure of skin to sunlight is beneficial in moderation since ultraviolet radiation is vital to the synthesis of vitamin D and hence to satisfactory skeletal development. Excessive exposure, however, is hazardous, particularly in light-skinned persons who tan poorly, and in patients who are photosensitive. There is also evidence that ultraviolet light decreases the immunological responses of the skin.

Photodamage is first evident as acute sunburn and, in the longer term, as premature ageing of the skin. Excessive exposure to sunlight also predisposes to the development of malignant and premalignant skin lesions, including actinic keratosis, squamous cell and basal cell carcinoma, and malignant melanoma.

The incidence of malignant and premalignant conditions is particularly high among light-skinned persons living in hot sunny climates and in dark-skinned persons with vitiligo or albinism. Many cases could be prevented by persuading parents and individuals directly at risk of the importance of avoiding sunburn and reducing exposure to solar radiation. Photoprotection in children is a priority all over the world, and every effort should be made to institute educational programmes on protection against the sun at a very early age. The use of protective clothing (e.g. tightly woven fabrics, wide-brimmed hats, long sleeves and long trousers) is highly effective. When this is not practicable or acceptable, it is important to encourage regular use of sunscreen products with a SPF rating of at least 15. People should understand that the atmosphere has a filtering effect on ultraviolet light and, therefore, they should avoid exposure at midday when the sun is most vertical and the light passes through less of the atmosphere.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 24 abril 2012